ArriVent BioPharma Inc (NASDAQ:AVBP) price on Thursday, July 03, fall -1.56% below its previous day’s close as a downside momentum from buyers pushed the stock’s value to $20.77.
A look at the stock’s price movement, the close in the last trading session was $21.1, moving within a range at $20.01 and $21.2. Turning to its 52-week performance, $36.37 and $15.47 were the 52-week high and 52-week low respectively. Overall, AVBP moved -10.16% over the past month.
ArriVent BioPharma Inc’s market cap currently stands at around $710.60 million, with investors looking forward to this quarter’s earnings report slated for on 2025-May-12.
Turning to the stock’s technical picture we see that short term indicators suggest on average that AVBP is a Hold. On the other hand, the stock is on average a 50% Sell as suggested by medium term indicators while long term indicators are putting the stock in 100% Sell category.
1 analyst(s) have given their forecast ratings for the stock on a scale of 1.00-5.00 for a strong buy to strong sell recommendation. A total of 0 analyst(s) rate the stock as a Hold, 1 recommend AVBP as a Buy and 0 give it an Overweight rating. Meanwhile, 0 analyst(s) rate the stock as Underweight and 0 say it is a Sell. As such, the average rating for the stock is Buy which could provide an opportunity for investors keen on increasing their holdings of the company’s stock.
AVBP’s current price about -10.62% and -4.05% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 39.60, while 7-day volatility ratio is 6.65% and 6.21% in the 30-day chart. Further, ArriVent BioPharma Inc (AVBP) has a beta value of 1.23. Analysts have given the company’s stock an average 52-week price target of $36, forecast between a low of $35 and high of $36. Looking at the price targets, the low is -68.51% off current price level while to achieve the yearly target high, price needs to move -73.33%. Nonetheless, investors will most likely welcome a -73.33% jump to $36 which is the analysts’ median price.
If we refocus on ArriVent BioPharma Inc (NASDAQ:AVBP), historical trading data shows that trading volumes averaged 0.63 over the past 10 days and 331.88K over the past 3 months. The company’s latest data on shares outstanding shows there are 34.04 million shares.
The 43.23% of ArriVent BioPharma Inc’s shares are in the hands of company insiders while institutional holders own 59.52% of the company’s shares. Also important is the data on short interest which shows that short shares stood at 5.02 million on 2025-06-13, giving us a short ratio of 14.99. The data shows that as of 2025-06-13 short interest in ArriVent BioPharma Inc (AVBP) stood at 2089.9999000000003 of shares outstanding, with shares short falling to 5.52 million registered in 2025-05-15. Current price change has pushed the stock 14.44% YTD, which shows the potential for further growth is there. It is this reason that could see investor optimism for the AVBP stock continues to rise going into the next quarter.
